Name: ORKA Cash Flow - Oruka Therapeutics Operating Cash & FCF | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Operating Cash Flow, Investing Cash Flow, Financing Cash Flow, Capital Expenditures, Free Cash Flow, Dividends Paid, Stock Buybacks, Net Change in Cash

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

ORKA - Oruka Therapeutics, Inc.

USD | NASDAQ | Healthcare

ORKA Cash Flow - Oruka Therapeutics Operating Cash & FCF | Ledgeburg

(in millions of USD)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17	Q3 FY 17	Q2 FY 17	Q1 FY 17	Q4 FY 16	Q3 FY 16	Q2 FY 16	Q1 FY 16
Net Income
Net Income	(31.8)	(29.6)	(30.3)	(24.6)	(21.0)	(28.6)	(22.2)	(2.0)	(1.1)	(1.4)	(1.5)	(1.3)	(1.2)	(2.3)	(3.1)	(3.3)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD)	TTM	FY2025	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007	FY2006	FY2005	FY2004
Net Income
Net Income	(116.3)	(105.4)	(5.3)	(9.9)	(19.3)	(9.7)	(5.5)	(7.9)	(18.5)	(16.4)	(11.4)	(9.7)	(6.9)	(4.3)	(5.4)	(8.4)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Cash From Operating Activities
Depreciation & Amortization	0.0	-	-	-	0.0	-	-	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-	0.0
Amortization Of Intangibles	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Compensation	7.0	4.1	10.2	5.1	4.9	9.0	0.7	0.1	0.1	0.2	0.2	0.2	0.1	0.1	0.2	0.2	0.1
Deffered Income Tax	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Asset Impairments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gains & Losses On Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change In Accounts Receivable	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change In Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change In Accounts Payable	-	-	-	-	-	-	-	0.2	-	-	-	0.0	-	-	-	(0.1)	-
Change In Other Working Capital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Operating Activities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash From Operating Activities	(23.6)	-	-	-	(20.9)	-	-	(1.5)	-	-	-	(1.6)	-	-	-

Cash From Investing Activities
Capital Expenditures	0.1	-	-	-	0.0	-	-	-	-	-	-	-	-	-	-	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-	-	-	-	-	0.0	-	-	-	-	-	-	-	0.0
Acquisitions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Divestitures	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase Of Investments	90.8	-	-	-	44.3	-	-	-	-	-	-	-	-	-	-	-	-
Sales Of Investments	76.5	-	-	-	87.2	-	-	-	-	-	-	-	-	-	-	-	-
Other Investing Activities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash From Investing Activities	(14.4)	-	-	-	42.9	-	-	0.0	-	-	-	0.0	-	-	-

Cash From Financing Activities
Debt Issued	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt Repaid	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common Stock Issuance	1.7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common Stock Repurchased	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Financing Activities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash From Financing Activities	40.6	-	-	-	-	-	-	0.0	-	-	-	0.0	-	-	-

Change In Cash & Equivalents
Effects Of Exchange Rate Changes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Change In Cash	-	-	-	-	-	-	-	(1.5)	-	-	-	(1.6)	-	-	-	(4.3)	-	-
Cash Beginning Of Period	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash End Of Period	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Free Cash Flow
Free Cash Flow	(23.7)	-	-	-	(20.9)	-	-	-	-	-	-	-	-	-	-	(4.3)	-	-	-	(5.2)	-	-	-	(1.7)	-	-	-	-	-	-	-	(3.1)	-	-	-	-	-	-	-	(3.9)
Free Cash Flow To Equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Free Cash Flow
Free Cash Flow	-	(88.4)	(5.0)	(10.9)	(18.8)	(7.7)	(4.8)	(8.2)	(17.5)	(15.0)	(10.5)	(9.4)	(5.3)	-	(7.0)	(8.3)	-	-	-	-	-	-
Free Cash Flow To Equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Cash Flow Statement